Unity Biotechnology Valuation
| UBX Stock | USD 1.83 0.13 7.65% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Unity Biotechnology has a current Real Value of $3.04 per share. The regular price of the company is $1.83. Our model measures the value of Unity Biotechnology from inspecting the company fundamentals such as Shares Outstanding of 16.87 M, shares owned by institutions of 19.58 %, and Return On Equity of -1.49 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Unity Biotechnology's valuation include:
Price Book 4.6494 | Enterprise Value | Enterprise Value Ebitda (0.23) | Price Sales 6.5445 | Enterprise Value Revenue 29.7906 |
Undervalued
Today
Please note that Unity Biotechnology's price fluctuation is dangerous at this time. Calculation of the real value of Unity Biotechnology is based on 3 months time horizon. Increasing Unity Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Unity Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Unity Stock. However, Unity Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.83 | Real 3.04 | Target 6.67 | Hype 1.93 | Naive 1.82 |
The intrinsic value of Unity Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Unity Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Unity Biotechnology helps investors to forecast how Unity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Unity Biotechnology more accurately as focusing exclusively on Unity Biotechnology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Unity Biotechnology's intrinsic value based on its ongoing forecasts of Unity Biotechnology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Unity Biotechnology's closest peers.
Unity Biotechnology Cash |
|
Unity Valuation Trend
Analysing the historical paterns of Unity Biotechnology's enterprise value and its market capitalization is a good way to estimate and gauge the value of Unity Biotechnology over time and is usually enough for investors to make rational market timing decisions.
Unity Biotechnology Total Value Analysis
Unity Biotechnology is at this time forecasted to have company total value of 30.5 M with market capitalization of 28.67 M, debt of 19.71 M, and cash on hands of 64.51 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Unity Biotechnology fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
30.5 M | 28.67 M | 19.71 M | 64.51 M |
Unity Biotechnology Asset Utilization
One of the ways to look at asset utilization of Unity is to check how much profit was generated for every dollar of assets it reports. Unity Biotechnology has a negative utilization of assets of -0.34 %, losing $0.003443 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Unity Biotechnology shows how discouraging it operates for each dollar spent on its assets.Unity Biotechnology Ownership Allocation
Unity Biotechnology shows a total of 16.87 Million outstanding shares. About 79.12 % of Unity Biotechnology outstanding shares are held by general public with 1.3 (%) owned by insiders and only 19.58 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Unity Biotechnology Profitability Analysis
Reported Net Loss for the year was (25.99 M) with loss before taxes, overhead, and interest of (13.01 M).About Unity Biotechnology Valuation
Our relative valuation model uses a comparative analysis of Unity Biotechnology. We calculate exposure to Unity Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Unity Biotechnology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -22.7 M | -23.8 M | |
| Pretax Profit Margin | (292.02) | (277.42) | |
| Operating Profit Margin | (280.54) | (266.51) | |
| Net Loss | (281.39) | (267.32) | |
| Gross Profit Margin | (7.41) | (7.78) |
Unity Biotechnology Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 16.8 M |
Unity Biotechnology Current Valuation Indicators
Valuation refers to the process of determining the present value of Unity Biotechnology and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Unity we look at many different elements of the entity such as Unity's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Unity Biotechnology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Unity Biotechnology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Unity Biotechnology's worth.Additional Tools for Unity Stock Analysis
When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.